Nurix Therapeutics Inc [NRIX] stock prices are up 6.62% to $10.14 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NRIX shares have gain 4.21% over the last week, with a monthly amount drifted -3.89%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nurix Therapeutics Inc [NASDAQ: NRIX] stock has seen the most recent analyst activity on March 17, 2025, when Leerink Partners initiated its Market Perform rating and assigned the stock a price target of $16. Previously, BTIG Research started tracking the stock with Buy rating on December 10, 2024, and set its price target to $35. On December 06, 2024, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $35 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $35 on October 24, 2024. Jefferies initiated its recommendation with a Buy and recommended $41 as its price target on October 11, 2024. In a note dated July 31, 2024, Truist initiated an Buy rating and provided a target price of $36 on this stock.
The stock price of Nurix Therapeutics Inc [NRIX] has been fluctuating between $8.18 and $29.56 over the past year. Currently, Wall Street analysts expect the stock to reach $22.67 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $10.14 at the most recent close of the market. An investor can expect a potential return of 123.57% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
The Nurix Therapeutics Inc [NASDAQ:NRIX] reported sales of 56.42M for trailing twelve months, representing a surge of 11.26%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -4.09%, Pretax Profit Margin comes in at -3.69%, and Net Profit Margin reading is -3.69%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.47 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Nurix Therapeutics Inc [NASDAQ:NRIX]’s Current Ratio is 6.26. As well, the Quick Ratio is 6.26, while the Cash Ratio is 0.84. Considering the valuation of this stock, the price to sales ratio is 13.70, the price to book ratio is 1.61.
Transactions by insiders
Recent insider trading involved van Houte Hans, Chief Financial Officer, that happened on May 02 ’25 when 6198.0 shares were sold. Officer, JOHANNES VAN HOUTE completed a deal on May 02 ’25 to buy 6198.0 shares. Meanwhile, Chief Scientific Officer Hansen Gwenn sold 3377.0 shares on Apr 30 ’25.
